Ausgabe 14/2014
Inhalt (11 Artikel)
Leading Article
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
David S. Perlin
Open Access
Review Article
Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
Toby Trujillo, Paul P. Dobesh
Open Access
Review Article
New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
Mohamad Mohty, Andrea Bacigalupo, Faouzi Saliba, Andreas Zuckermann, Emmanuel Morelon, Yvon Lebranchu
Review Article
Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD
Lorraine Murphy, Stephen Rennard, James Donohue, Mathieu Molimard, Ronald Dahl, Kai-Michael Beeh, Juergen Dederichs, Hans-Jürgen Fülle, Mark Higgins, David Young
Adis Drug Evaluation
Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly
Celeste B. Burness, Sohita Dhillon, Susan J. Keam
Adis Drug Evaluation
Omalizumab: A Review of Its Use in Patients with Chronic Spontaneous Urticaria
Paul L. McCormack
Letter to the Editor
Comment on “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”
Daniel Wendling, Clément Prati
Letter to the Editor
Author's Reply to Wendling and Prati: “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”
James Cheng-Chung Wei